Neumifil
Prophylaxis & Treatment of Viral Respiratory Tract Infections (Influenza, RSV, Rhinovirus, Coronavirus)
Key Facts
About Pneumagen
Pneumagen is a UK-based, clinical-stage biotechnology company pioneering a novel approach to combating viral respiratory infections. Its lead candidate, Neumifil, is an intranasal, broad-spectrum antiviral derived from its proprietary GlycoTarge™ platform, which has shown positive Phase 2 results in a human influenza challenge study. The company is strategically targeting the large market of patients with chronic respiratory diseases like COPD, who are vulnerable to severe viral exacerbations. With a seasoned leadership team and a clear development path, Pneumagen aims to advance Neumifil into further clinical trials to address a major unmet need.
View full company profile